Guinness Ventures focuses on supporting companies that are already generating revenue.
The funding round was backed by Guinness Ventures, Conduit Fund, Octopus Ventures, and Macmillan Cancer Support, exceeding the company's initial €2m target.
"Supporting businesses developing scalable, meaningful impact in healthcare is a priority for us,"
Guinness Ventures led the round, with additional backing from Scottish Enterprise, Growthdeck, The SideBySide Partnership, Equity Gap, and Virgin Money.
"This investment accelerates our mission to deliver game improvement technology to 60 million golfers around the world. Throughout 2024 we plan to invest in infrastructure across the USA to support our retail and distribution partners. Golfers globally love our GPS, rangefinder and shot-tracking technology, having sold products in 160 different countries worldwide in 2023. Golf has experienced a huge change in the past 5 years, people of all ages and demographics love the sport. With Shot Scope golfers can improve quickly and enjoy the game they love even more."
Guinness Ventures led the Series B round alongside participants including Scottish Enterprise, Growthdeck, and Virgin Money.
"This investment accelerates our mission to delivergame improvement technology to 60 million golfers around the world. Throughout 2024 we plan to invest in infrastructure across the USA to support our retail and distribution partners. Golfers globally love our GPS, rangefinder and shot tracking technology, having sold products in 160 different countries worldwide in 2023. Golf has experienced a huge change in the past 5 years, people of all ages and demographics love the sport. With Shot Scope golfers can improve quickly and enjoy the game they love even more."
Hargreave Hale AIM VCT led the financing round to help accelerate the company platform and expand into new disease areas.
"The close of our Series A round marks the 'end of the beginning' and the start of a new chapter for Qureight, as we turn our focus to developing our platform and creating products in new disease areas. Our mission to extend the lives of lung and heart disease patients will be bolstered by the invaluable expertise of our new board and new senior team members, and we are looking forward to adding to our strategic biopharma collaborations."
Beringea led the growth round for the patient review platform, with continued support from Keen Venture Partners, Amadeus Capital Partners, and Guinness Ventures.
"Our health is the most precious thing we have. With Doctify, we are working on building the world’s most important healthcare platform to help millions of patients. We are excited to welcome our new investors, Beringea, whom we first met years ago, and we are delighted with the support of our existing investors."
